Daily aspirin use, even at low doses, may reduce mortality among men with high-risk non metastatic prostate cancer, according to research published online Oct. 20 in the Journal of Clinical Oncology.
Eric J. Jacobs, of the American Cancer Society in Atlanta, and colleagues analysed data for men diagnosed with non metastatic prostate cancer to assess the association between daily aspirin use and prostate cancer-specific mortality (PCSM). The men were enrolled in the Cancer Prevention Study-II Nutrition Cohort between 1992 or 1993 and June 2009, and followed up through 2010.
The researchers found that, after multi-variable adjustment, neither pre diagnosis (hazard ratio [HR], 0.92; 95 percent confidence interval [CI], 0.72 to 1.17) nor post diagnosis (HR, 0.98; 95 percent CI, 0.74 to 1.29) daily use of aspirin showed a statistically significant association with PCSM compared with no aspirin use. Among men diagnosed with high-risk cancers (≥T3 and/or Gleason score ≥8), post diagnosis daily aspirin use was associated with lower PCSM (HR, 0.60; 95 percent CI, 0.37 to 0.97). In this subgroup, no difference in mortality risk was observed according to aspirin dose, such as the typical low dose of 81 mg per day (HR, 0.50; 95 percent CI, 0.27 to 0.92) or higher doses (HR, 0.73; 95 percent CI, 0.40 to 1.34).
“A randomised trial of aspirin among men diagnosed with non metastatic prostate cancer was recently funded,” the authors write. “Our results suggest any additional randomised trials addressing this question should prioritise enrolling men with high-risk cancers and need not use high doses.”
One author disclosed financial ties to Bayer.